RARE DISEASE
Localized scleroderma
Localized scleroderma
Localized scleroderma
Synonyms: Localized fibrosing scleroderma
Synonyms: Localized fibrosing scleroderma
Synonyms: Localized fibrosing scleroderma
Drug discovery
3
drugs
With orphan designations
Overview
Localized scleroderma (LS) is an autoimmune disorder characterized by collagen overproduction, causing skin fibrosis and inflammation without systemic organ involvement. It presents as morphea (circumscribed plaques) or linear scleroderma (streaks affecting skin, muscle, or bone). While primarily cutaneous, deep tissue involvement may lead to limb asymmetry, joint contractures, or facial deformities. Diagnosis relies on clinical assessment and biopsy confirmation.
Burden
Disability-adjusted life years (DALY) disproportionately affect ages 15–54, driven by chronic disability [4].
Extracutaneous complications (e.g., musculoskeletal, neurological) occur in 20% of pediatric cases [6][19].
Quality-of-life impacts include disfigurement, pain, and fatigue, despite non-life-threatening progression [14][19].
Categories: rare skin diseases
Research Papers
852 drug discovery papers related to Localized scleroderma, with 3 first-in-class and 2 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
852 drug discovery papers related to Localized scleroderma, with 3 first-in-class and 2 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-03 | Spatial Orchestration of Skin Fibrosis by a CD8+ T cell-Myofibroblast Axis.
Fibrosing skin diseases are highly morbid conditions with diverse clinical and histopathologic features. Prior work, primarily in systemic sclerosis (SSc), has yielded mixed data regarding the immune drivers of fibrosis, as well as the identity and spatial localization of pro-fibrotic fibroblast cell subsets. Here, we focus on morphea and eosinophilic fasciitis (EF), which cause more acutely inflammatory skin fibrosis. Using multimodal single-nucleus and spatial transcriptomics, we find that effector CD8+ T cells are highly enriched in fibrotic skin. These cells are particularly abundant in inflammatory tissue domains bordering fibrotic stroma, which are marked by expression of interferon-γ stimulated genes. Inflammatory domains feature a loss of local homeostatic fibroblast populations and replacement with ADAM12-expressing inflammatory fibroblasts and myofibroblasts, which co-localize closely with CD8+ T cells. All subtypes of morphea featured similar patterns of CD8+ T-cell-associated fibro-inflammatory zonation and fibroblast transformation, suggesting that shared mechanisms can drive fibrosis across stromal compartments of skin. We apply these findings to a large publicly available scleroderma dataset and find that similar processes occur in SSc. Mechanistically, ablation of CD8+ T cells in mice ameliorates bleomycin-driven inflammation and fibrosis, as does fibroblast-intrinsic abrogation of IFN-γ signaling. These data establish CD8+ T cell-driven fibrogenesis as a key feature of fibrosing skin diseases and raise the prospect of targeting CD8+ T cells in autoimmune fibrosis more broadly. Spatial profiling of morphea-spectrum diseases reveals CD8 T cells as key drivers of fibrosis through fibroblast IFN-γ signaling.
2026-06-22 | Pioglitazone in Skin Fibrosis: Mechanistic Rationale and Therapeutic Potential of Pioglitazone for Scarring Dermatoses.
Cutaneous fibrosis - encompassing keloids, hypertrophic scars, localized scleroderma (morphea), and scarring alopecias - remains fundamentally undertreated, with conventional interventions frequently yielding incomplete therapeutic responses and high rates of recurrence. Pioglitazone, a Food and Drug Administration (FDA)-approved peroxisome proliferator-activated receptor γ (PPAR-γ) agonist traditionally utilized for glycemic control in type 2 diabetes mellitus, represents a highly compelling candidate for dermatologic repurposing. Beyond its canonical metabolic functions, robust target engagement of PPAR-γ by pioglitazone suppresses NF-κB-driven cytokine cascades, directly inhibits NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome assembly, promotes macrophage polarization toward tissue-reparative phenotypes, and disrupts profibrotic TGF-β/SMAD signaling architectures. Consequently, the drug exerts a dual mechanism of action, simultaneously attenuating chronic inflammation while inhibiting pathological fibrogenesis. This review expands upon prior analyses by integrating recently published clinical and scientific data, specifically highlighting new translational milestones, including human registry data in progeroid syndromes and randomized controlled trials in cicatricial alopecia. A distinct focus is placed on advancements in localized delivery strategies, such as nanostructured lipid carriers and niosomes, that offer the potential to overcome pioglitazone's inherent physicochemical constraints and thereby maximize dermal target engagement while avoiding systemic toxicities like heart failure and bladder cancer. Furthermore, this analysis synthesizes recent molecular insights connecting fibrosis and inflammation via target engagement biomarkers (e.g., FABP4, CD36) and proposes actionable, biomarker-driven trial designs, including adaptive basket trials, to bridge current gaps in dermatology-specific translation. Demonstrating localized anti-fibrotic and anti-inflammatory efficacy with minimal systemic risk could establish pioglitazone as a mechanism-based, disease-modifying therapy for a broad spectrum of fibrotic and scarring dermatologic disorders.
2026-06-19 | Late-Onset En Coup de Sabre: A Rare Presentation of Linear Scleroderma in an Elderly Woman.
En coup de sabre (ECDS) is a rare form of linear scleroderma that typically presents in childhood and may lead to progressive craniofacial tissue atrophy. Adult-onset disease is uncommon and may delay recognition. Early identification is important to prevent permanent deformity and potential neurologic complications. A 60-year-old woman with no significant past medical history presented with a nine-month history of progressive hyperpigmentation, skin tightening, and indentation involving the nasal bridge and left frontoparietal region. Over time, the discoloration extended toward the right forehead and was associated with contour changes of the nasal bridge and left forehead. Laboratory evaluation revealed a positive anti-histone antibody, with no evidence of systemic autoimmune or infectious disease. Imaging and endoscopic evaluation excluded sinonasal, bony, and intracranial pathology. Skin biopsy findings were consistent with a localized sclerosing process. A diagnosis of linear scleroderma ECDS was established. The patient was initiated on systemic corticosteroid therapy along with topical treatment and referred for multidisciplinary management. This case highlights an atypical late-onset presentation of ECDS. Although most cases occur in pediatric populations, adult-onset disease can present diagnostic challenges and may be associated with delayed recognition. The potential for neurologic involvement, even in the absence of initial symptoms, underscores the importance of careful evaluation and monitoring. Linear scleroderma ECDS should be considered in adults presenting with progressive craniofacial atrophy. Early diagnosis, prompt initiation of therapy, and ongoing neurologic surveillance are essential to reduce the risk of long-term functional and cosmetic sequelae.
2026-07-03 | Spatial Orchestration of Skin Fibrosis by a CD8+ T cell-Myofibroblast Axis.
Fibrosing skin diseases are highly morbid conditions with diverse clinical and histopathologic features. Prior work, primarily in systemic sclerosis (SSc), has yielded mixed data regarding the immune drivers of fibrosis, as well as the identity and spatial localization of pro-fibrotic fibroblast cell subsets. Here, we focus on morphea and eosinophilic fasciitis (EF), which cause more acutely inflammatory skin fibrosis. Using multimodal single-nucleus and spatial transcriptomics, we find that effector CD8+ T cells are highly enriched in fibrotic skin. These cells are particularly abundant in inflammatory tissue domains bordering fibrotic stroma, which are marked by expression of interferon-γ stimulated genes. Inflammatory domains feature a loss of local homeostatic fibroblast populations and replacement with ADAM12-expressing inflammatory fibroblasts and myofibroblasts, which co-localize closely with CD8+ T cells. All subtypes of morphea featured similar patterns of CD8+ T-cell-associated fibro-inflammatory zonation and fibroblast transformation, suggesting that shared mechanisms can drive fibrosis across stromal compartments of skin. We apply these findings to a large publicly available scleroderma dataset and find that similar processes occur in SSc. Mechanistically, ablation of CD8+ T cells in mice ameliorates bleomycin-driven inflammation and fibrosis, as does fibroblast-intrinsic abrogation of IFN-γ signaling. These data establish CD8+ T cell-driven fibrogenesis as a key feature of fibrosing skin diseases and raise the prospect of targeting CD8+ T cells in autoimmune fibrosis more broadly. Spatial profiling of morphea-spectrum diseases reveals CD8 T cells as key drivers of fibrosis through fibroblast IFN-γ signaling.
2026-06-22 | Pioglitazone in Skin Fibrosis: Mechanistic Rationale and Therapeutic Potential of Pioglitazone for Scarring Dermatoses.
Cutaneous fibrosis - encompassing keloids, hypertrophic scars, localized scleroderma (morphea), and scarring alopecias - remains fundamentally undertreated, with conventional interventions frequently yielding incomplete therapeutic responses and high rates of recurrence. Pioglitazone, a Food and Drug Administration (FDA)-approved peroxisome proliferator-activated receptor γ (PPAR-γ) agonist traditionally utilized for glycemic control in type 2 diabetes mellitus, represents a highly compelling candidate for dermatologic repurposing. Beyond its canonical metabolic functions, robust target engagement of PPAR-γ by pioglitazone suppresses NF-κB-driven cytokine cascades, directly inhibits NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome assembly, promotes macrophage polarization toward tissue-reparative phenotypes, and disrupts profibrotic TGF-β/SMAD signaling architectures. Consequently, the drug exerts a dual mechanism of action, simultaneously attenuating chronic inflammation while inhibiting pathological fibrogenesis. This review expands upon prior analyses by integrating recently published clinical and scientific data, specifically highlighting new translational milestones, including human registry data in progeroid syndromes and randomized controlled trials in cicatricial alopecia. A distinct focus is placed on advancements in localized delivery strategies, such as nanostructured lipid carriers and niosomes, that offer the potential to overcome pioglitazone's inherent physicochemical constraints and thereby maximize dermal target engagement while avoiding systemic toxicities like heart failure and bladder cancer. Furthermore, this analysis synthesizes recent molecular insights connecting fibrosis and inflammation via target engagement biomarkers (e.g., FABP4, CD36) and proposes actionable, biomarker-driven trial designs, including adaptive basket trials, to bridge current gaps in dermatology-specific translation. Demonstrating localized anti-fibrotic and anti-inflammatory efficacy with minimal systemic risk could establish pioglitazone as a mechanism-based, disease-modifying therapy for a broad spectrum of fibrotic and scarring dermatologic disorders.
2026-06-19 | Late-Onset En Coup de Sabre: A Rare Presentation of Linear Scleroderma in an Elderly Woman.
En coup de sabre (ECDS) is a rare form of linear scleroderma that typically presents in childhood and may lead to progressive craniofacial tissue atrophy. Adult-onset disease is uncommon and may delay recognition. Early identification is important to prevent permanent deformity and potential neurologic complications. A 60-year-old woman with no significant past medical history presented with a nine-month history of progressive hyperpigmentation, skin tightening, and indentation involving the nasal bridge and left frontoparietal region. Over time, the discoloration extended toward the right forehead and was associated with contour changes of the nasal bridge and left forehead. Laboratory evaluation revealed a positive anti-histone antibody, with no evidence of systemic autoimmune or infectious disease. Imaging and endoscopic evaluation excluded sinonasal, bony, and intracranial pathology. Skin biopsy findings were consistent with a localized sclerosing process. A diagnosis of linear scleroderma ECDS was established. The patient was initiated on systemic corticosteroid therapy along with topical treatment and referred for multidisciplinary management. This case highlights an atypical late-onset presentation of ECDS. Although most cases occur in pediatric populations, adult-onset disease can present diagnostic challenges and may be associated with delayed recognition. The potential for neurologic involvement, even in the absence of initial symptoms, underscores the importance of careful evaluation and monitoring. Linear scleroderma ECDS should be considered in adults presenting with progressive craniofacial atrophy. Early diagnosis, prompt initiation of therapy, and ongoing neurologic surveillance are essential to reduce the risk of long-term functional and cosmetic sequelae.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Localized scleroderma.
3 orphan drug designations for Localized scleroderma.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex | cell therapies | FDA | 2016-04-19 | — | Castle Creek Biosciences, LLC |
Peptide 144 TGF beta-1-inhibitor | peptides | FDA | 2006-04-26 | — | Digna Biotech, S.L. |
Peptide 144 TGF- ß1 inhibitor (TSLDASIIWAMMQN) | peptides | EMA | 2005-10-28 | — | Digna Biotech S.L. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.